Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
How to support someone who is grieving: five research-backed strategies 
Office design isn’t keeping up with post-COVID work styles - here’s what workers really want 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Oil Prices Rebound as U.S.-Venezuela Tensions Offset Oversupply Concerns 
Silver Prices Hit Record High as Safe-Haven Demand Surges Amid U.S. Economic Uncertainty 
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk 
The American mass exodus to Canada amid Trump 2.0 has yet to materialize 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
Stuck in a creativity slump at work? Here are some surprising ways to get your spark back 
AI is driving down the price of knowledge – universities have to rethink what they offer 
China’s Small Bank Consolidation Struggles as Profits Fall and Risks Persist 
Locked up then locked out: how NZ’s bank rules make life for ex-prisoners even harder 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Coca-Cola Japan and Kirin Holdings will develop health drinks that contain the live bacteria, lactococcus lactis strain plasma (LC-Plasma), an ingredient patented by Kirin that is used in the company's health drinks.
Kirin claims that the live bacteria boosts immunity in healthy people.
Kirin is the first among companies that make foods and beverages they claim to boost immunity to have been approved by Japan's Consumer Affairs Agency in 2020 to advertise its products as such.
Coca-Cola Japan plans to put LC-Plasma into three of its brands, Georgia, Irohasu, and Minute Maid.
The Consumer Affairs Agency has also given the go-ahead for the drinks to be advertised as having the advantage.
The partnership demonstrates Coca-Cola Japan's intention to improve its position in the health beverage market. According to market research firm Inryo Soken, Coca-Cola has a 26 percent market share in soft drinks but has not advanced significantly in the market for health beverages.
On the other hand, Kirin is increasing sales of its LC-Plasma component and sees health products as its next area of growth. It anticipates that by 2027, sales of health drinks will have increased fivefold from their current level to 50 billion yen.
Taisho Pharmaceutical Holdings, as well as candy manufacturers including Morinaga & Co. and Kanro, have already purchased the component from Kirin.
Although supplying a rival with distinctive ingredients would negate Kirin's advantage, collaborating with Coca-Cola might let it expand its market.
